A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome

Trial Profile

A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2014

At a glance

  • Drugs Isunakinra (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Sponsors Eleven Biotherapeutics
  • Most Recent Events

    • 15 May 2014 Data was presented at the 2014 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, according to an Eleven Biotherapeutics media release.
    • 15 May 2014 Data was presented at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium, according to an Eleven Biotherapeutics media release.
    • 20 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top